If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
] (see supplement S1 for presumed mode of action). The authors now present clinical outcome data of this treatment approach in form of an open label case series.
Nine consecutive patients (4 female) suffering from severe treatment-resistant OCD (mean duration of disease = 23.4 years, range 11–39 years) with a mean age of 39.2 years (range 25–52 years) have been treated with DBS of the slMFB by our research group (see supplement S2 for sample selection). All patients received various disease-specific prior treatments, reported substantial impairment in their daily life due to OCD symptoms and were classified as treatment-resistant by our multi-professional and specialized team (psychiatrists and psychologists) based on comprehensive visits and provided medical documents. They underwent DBS surgery between December 2017 and January 2020 and were followed up. The neurosurgical procedure including imaging, fiber tracking, surgery and postoperative care has been described in detail in patients with treatment-resistant depression [
] all patients received segmented DBS electrodes (Vercise Cartesia, Boston Scientific, Valencia, USA). Eight patients received a rechargeable pulse generator (Vercise Gevia, Boston Scientific); one patient received a non-rechargeable pulse generator (Vercise PC, Boston Scientific). Pulse generators were placed subclavicularly.
Comprehensive symptom development (clinical outcome) was assessed regularly up to 36 months following stimulation onset, using clinician-based psychometric measurements (see supplement S3 and S4). We here focus on the Yale-Brown obsessive compulsive scale (Y-BOCS) [
]) and three other patients reached >20% reduction of Y-BOCS sum score at this time point.
Mean duration until response criterion was reached for the first time was three months (ranging from stimulation onset to eight months). After one year of stimulation (range 10–13 months) seven patients were classified as responders and sustained response until last follow-up (FU, ranging from 11 to 36 months of stimulation, depending on date of surgery). Two patients responded occasionally only (Fig. 1F). As three-month data is available for six out of nine patients, this time point has been selected for short-term evaluation: By this time, mean Y-BOCS sum score had decreased by 43.1% (SD = 23.6, n = 6) compared to baseline. This score had decreased by 55.9% (SD = 20.0) after one year of stimulation and by 53.5% (SD = 23.7) at last FU. In absolute numbers this refers to a mean reduction of 12.2 points (SD = 6.7, n = 6) at three months, 16.9 (SD = 5.4) after one year and 16.2 (SD = 6.7) at last FU. For absolute scores see supplement Table S1, where improvement of depressive symptoms and global functioning is depicted, as well.
Current applied therapeutically ranged between 1.4 and 5.5mA. For detailed information on stimulation settings see supplement S7. Stimulation related side effects resembled the ones described in previous publications on slMFB DBS in depression [
] but exceed this rate notably in the long run. Regarding size equivalent studies, some agreement with the clinical effects we report here, was achieved by DBS of the anteromedial subthalamic nucleus (amSTN) in a comparably affected sample with OCD (n = 8) [
]. Three months of amSTN stimulation resulted in 13 points reduction of Y-BOCS score whereas we achieved 12.2 points reduction (n = 6) in the same time frame. The long-term outcome with 51.2% (SD = 21.2) reduction rate after 46 months (n = 12) and 9/11 responders [
]. The comparison with existing literature demonstrates that DBS of the slMFB might reduce OCD symptoms just as much or even more than DBS of other targets and supports further research on efficacy and safety of this target.
Beyond OCD symptoms, eventually depressive symptoms decreased quickly after stimulation onset in seven patients (supplement Table S1). This antidepressant effect is not surprising but expectable as previous studies on DBS of the slMFB in treatment-resistant depression have demonstrated rapid response onsets [
]. Further imaging studies proving this hypothesis on a functional level are pending.
Generally, results of this report have to be interpreted cautiously as this is an open-label case series. Although visits at our unit are standardized, we did not follow a formalized research protocol. This results in continuous open stimulation without controlled sham-phases and might result in an overestimation of improvement as well as the unstable concomitant medication and psychotherapy. Therefore, future studies should be designed as RCTs to generate deeper insight into the efficacy and safety-profile of the treatment. Nevertheless, considering the enormous burden of illness of OCD in its severest form as reported here, the large effect, the long-term efficacy data and the safety-profile reported, we believe that this report clearly makes the point of adding the slMFB to brain stimulation target studies for this disease.
This manuscript has not been previously published other than in form of abstracts and is not currently under consideration by any other journal. Part of the data have been presented in abstracts/poster sessions at the ACNP annual meetings 2018 (Hollywood, FL) and 2019 (Orlando, FL) and at the DGPPN Congress 2018 (Berlin, Germany). We have since then acquired additional data that make our results more reliable.
This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.
Declaration of competing interest
The authors disclose the following:
Dora M Meyer's and Susanne Spanier's positions are funded by a research grant provided to Thomas E Schlaepfer by Boston Scientific (USA).
Hannah M Kilian reports no financial relationships with commercial interests.
Marco Reisert reports no financial relationships with commercial interests.
received honoraria from Biogen, Eisai, mbits.
serves as an advisory member for Biogen.
Bastian E A Sajonz receives a research grant from CereGate unrelated to this project.
Peter C Reinacher
receives research support from Else Kröner-Fresenius Foundation (Germany) and Fraunhofer Foundation (Germany).
Received personal honoraria for lectures or advice from Boston Scientific (USA) and Brainlab (Germany).
Is consultant for Boston Scientific (USA), Inomed (Germany) and Brainlab (Germany).
received speakers honoraria and advisory panel payments from Janssen; and DMC panel payments from Novartis.
is an investigator in clinical trials for Janssen, Intracellular Therapeutics and Ketabon.
Katharina Domschke is a member of the Janssen Pharmaceuticals, Inc. Steering Committee Neurosciences.
Volker A Coenen
serves on the scientific advisory boards of CereGate (Munich, Germany),CorTec (Freiburg, Germany) and InBrain (Barcelona, Spain).
has received honoraria and travel support for talks from Boston Scientific.
has received grants for IITs from Medtronic and Boston Scientific.
receives an ongoing collaborative grant from BrainLab (Munich, Germany).
Thomas E Schlaepfer.
Received honoraria for an expert opinion from LivaNova Inc.
was reimbursed for attendance fees for congresses or training sessions with a topic related to this article and travel expenses by Medtronic Inc.
received honoraria for the preparation of lectures or scientific conferences or training events related to this article's topic from Medtronic Inc., LivaNova Inc., Medforum Sp. zo.o., Neuro-Consil GmbH, Sage Therapeutics Inc.
received honoraria for a clinical contract study related to the topic of this article by LivaNova Inc.
received honoraria for an investigator initiated trial (IIT) related to the topic of this article from Boston Scientific.
We thank our patients for their trust and their consent to this publication. We thank Lars Greβ for data preparation and Pauline Turk for literature search.
Appendix A. Supplementary data
The following is the Supplementary data to this article: